Norway rat Vegfa Lentivirus plasmid
Cat:pGMLV000815
If you purchase ORF/cDNA clone-Lentivirus plasmid, ORF vector will be delivered with P-ALV-B11 backbone together.
Availability:3-7 business days
Description
Catalog ID
pGMLV000815
Gene Name
Vegfa
Product Name
Norway rat Vegfa Lentivirus plasmid
Accession Number
NM_001287107.1
Gene ID
83785
Species
Norway rat
Product Type
Lentivirus plasmid
Insert Length
645
Gene Alias
VPF; Vegf; VEGF-A; VEGF111; VEGF164
Fluorescent Label
RFP-PURO
Fusion Tag
3×flag
Promoter
CMV
Resistance
Amplicin
gene description
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]
Maker
RFP-PURO
Regulation
overexpression